Market LIVE
Published markets; coverage varies by country
Product profile · United States

FIRAZYR

 ·  Patent Litigation & Settlement History ↓

IngredientICATIBANT ACETATE
Application typeNDA
Application022150
Product001
Dosage formINJECTABLE
RouteSUBCUTANEOUS
StrengthEQ 30MG BASE/3ML (EQ 10MG BASE/ML)
Approval date2011-08-25
Marketing statusPrescription
Status event—
ApplicantTAKEDA PHARMS USA
Product source

Current GenericRadar decision

Year2019
SelectionEXISTING_GENERIC
ReviewDISQUALIFIED
Anchor typeFINAL_ANDA
Anchor date2019-07-15
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2019-07-15
Status event—

Exact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
No patent facts are recorded for this product.

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
210118 / 001FINAL_APPROVAL · FINAL_APPROVED2019-07-15—TEVA PHARMACEUTICALS USA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211021 / 001FINAL_APPROVAL · FINAL_APPROVED2020-03-09—JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208317 / 001FINAL_APPROVAL · FINAL_APPROVED2020-06-18—FRESENIUS KABI USA LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212446 / 001FINAL_APPROVAL · FINAL_APPROVED2020-07-13—CIPLA LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211501 / 001FINAL_APPROVAL · FINAL_APPROVED2020-09-01—WILSHIRE PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213054 / 001FINAL_APPROVAL · FINAL_APPROVED2020-10-05—CAPLIN STERILES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212081 / 001FINAL_APPROVAL · FINAL_APPROVED2020-12-16—NANG KUANG PHARMACEUTICAL CO LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213222 / 001FINAL_APPROVAL · FINAL_APPROVED2021-05-21—GLENMARK PHARMACEUTICALS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213521 / 001FINAL_APPROVAL · FINAL_APPROVED2023-08-14—EUGIA PHARMA SPECIALITIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213773 / 001FINAL_APPROVAL · FINAL_APPROVED2024-06-14—ALEMBIC PHARMACEUTICALS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 10 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
210118 / 001TEVA PHARMACEUTICALS USA INCFINAL_APPROVAL · FINAL_APPROVED2019-07-15 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211021 / 001JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTDFINAL_APPROVAL · FINAL_APPROVED2020-03-09 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208317 / 001FRESENIUS KABI USA LLCFINAL_APPROVAL · FINAL_APPROVED2020-06-18 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212446 / 001CIPLA LTDFINAL_APPROVAL · FINAL_APPROVED2020-07-13 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211501 / 001WILSHIRE PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2020-09-01 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213054 / 001CAPLIN STERILES LTDFINAL_APPROVAL · FINAL_APPROVED2020-10-05 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212081 / 001NANG KUANG PHARMACEUTICAL CO LTDFINAL_APPROVAL · FINAL_APPROVED2020-12-16 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213222 / 001GLENMARK PHARMACEUTICALS LTDFINAL_APPROVAL · FINAL_APPROVED2021-05-21 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213521 / 001EUGIA PHARMA SPECIALITIES LTDFINAL_APPROVAL · FINAL_APPROVED2023-08-14 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213773 / 001ALEMBIC PHARMACEUTICALS LTDFINAL_APPROVAL · FINAL_APPROVED2024-06-14 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Decision evidence (1)
TypeDateRoleBasisSource
GENERIC2019-07-15TERMINAL_GENERIC_BASISExact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.